Current guidelines recommend anticoagulation (AC) for low and intermediate-risk
pulmonary embolism (PE) and systemic thrombolysis (tPA) for high risk (massive) PE. How …

Objective: The objective of this study is to compare the efficacy and safety of thrombolysis
plus anticoagulant therapy vs. anticoagulant therapy alone in acute submassive pulmonary …

Purpose The aim of this systematic review was to evaluate the efficacy and safety of
thrombolytic treatment in patients with submassive pulmonary embolism (PE). Methods An …

Background The optimal therapy for submassive pulmonary embolism remains in question.
The following meta-analysis compiles the current evidence comparing Catheter-Directed …

Background: Pulmonary emboli (PE) represents an extended spectrum of diseases. 10% of
submassive PE progress to massive PE, and while overall mortality is around 5%, it can …

There are limited and conflicting data on the initial management of intermediate-risk (or
submassive) pulmonary embolism (PE). This study sought to compare the outcomes of …

Therapy for submassive pulmonary embolism (intermediate risk), remains controversial.
New evidence has appeared that may help us in the process of decision making. We review …

Background The efficacy of thrombolytic therapy in patients with submassive pulmonary
embolism (PE) remains unclear. Previous meta‐analyses have not separately reported the …

Background Benefit of thrombolytic therapy in patients with massive pulmonary embolism
(PE) is evident. However, evidence supporting benefit in clinical outcomes of this approach …

Studies have provided evidence of PE-associated right ventricular (RV) dysfunction as the
most common cause of death during the first 30 days after the diagnosis of PE. 2, 3 The …